Riyadh: The fourth edition of the Riyadh Global Medical Biotechnology Summit 2026 concluded yesterday, featuring more than 40 agreements, initiatives, and announcements as part of partnerships, programs, and projects with a combined estimated value exceeding SAR5 billion. These aim to support biotechnology localization and enhance its health and economic impact. According to Saudi Press Agency, the summit drew delegations and experts from more than 57 countries and more than 200 speakers. The total number of visitors and registrants exceeded 15,000. Its program included more than 80 sessions, along with seven high-level executive sessions, covering artificial intelligence, genomics, vaccines, biomanufacturing, advanced therapies, investment, and talent development. The Life Sciences Innovation Forum attracted five specialized investment funds that expressed readiness to invest more than $120 million in promising opportunities and companies. Meanwhile, the Next Generation Biotechnologist Forum focused on emp owering early-career researchers and scientists. The accompanying exhibition spanned more than 6,000 square meters and featured more than 120 sponsors and exhibitors, including international pavilions from Spain, China, Japan, Germany, the United States of America, and the Republic of Korea.